VITT (vaccine-induced immune thrombocytopenia and thrombosis) is a rare blood clotting condition linked to adenovirus-based COVID vaccines, such as the AstraZeneca jab.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific ...
SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting ...
New tick-borne bacteria discovered in dogs in the US, Rickettsia finnyi, is very similar to canine spotted fever.
Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.
CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences conference, highlighting plans to init ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...
Detailed price information for X4 Pharmaceuticals Inc (XFOR-Q) from The Globe and Mail including charting and trades.
Romiplostim prevents chemotherapy-induced thrombocytopenia or low platelet count, reducing bleeding risks in cancer patients ...
“There is a method to how these decisions historically have been made,” Murphy wrote in his 45-page opinion, “a method ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results